Drug intelligence / Profile preview

WH006

Development stage: Unknown
Lead developer: Beijing Wehand-Bio Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

WH006 is a small molecule natural product-based drug being developed by Beijing Wehand-Bio Pharmaceutical for the treatment of obesity and adult weight loss. The drug is derived from mulberry twig alkaloids (referred to as SZ-A), which is the same active pharmaceutical ingredient used in the company's approved type 2 diabetes medication, Sangborn. WH006 is designed to act via the AMPK (AMP-activated protein kinase) pathway to regulate energy metabolism and promote weight reduction. It is currently in Phase 2 clinical development and is administered orally in a tablet formulation.

Other names: Mulberry Twig AlkaloidsSZ-A

Targets

AMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on WH006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WH006.

Explore the full profile